Cantor Fitzgerald Forecasts VKTX FY2025 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Viking Therapeutics in a report released on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the biotechnology company will earn ($2.57) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Viking Therapeutics' current full-year earnings is ($1.56) per share.

A number of other equities analysts have also recently issued reports on the stock. Citigroup started coverage on shares of Viking Therapeutics in a research note on Friday, February 7th. They issued a "neutral" rating and a $38.00 price objective for the company. B. Riley reissued a "buy" rating and set a $96.00 target price (down from $109.00) on shares of Viking Therapeutics in a research note on Friday, February 7th. The Goldman Sachs Group initiated coverage on Viking Therapeutics in a research report on Tuesday, April 8th. They set a "neutral" rating and a $30.00 price target for the company. Truist Financial reiterated a "buy" rating and issued a $75.00 target price (down from $95.00) on shares of Viking Therapeutics in a research note on Monday, April 28th. Finally, Maxim Group decreased their price target on shares of Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $87.15.

Viking Therapeutics Trading Down 7.7 %

VKTX traded down $2.28 during trading on Thursday, hitting $27.21. The stock had a trading volume of 1,920,343 shares, compared to its average volume of 4,093,650. The firm has a market cap of $3.06 billion, a PE ratio of -27.19 and a beta of 0.75. The company has a 50 day simple moving average of $26.21 and a 200-day simple moving average of $38.78. Viking Therapeutics has a 12 month low of $18.92 and a 12 month high of $81.86.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). During the same quarter in the prior year, the business posted ($0.26) earnings per share. The business's quarterly revenue was up .0% compared to the same quarter last year.

Insider Buying and Selling

In other news, Director Sarah Kathryn Rouan purchased 1,240 shares of the stock in a transaction dated Monday, March 31st. The shares were purchased at an average cost of $24.15 per share, with a total value of $29,946.00. Following the completion of the acquisition, the director now owns 1,240 shares in the company, valued at $29,946. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 4.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Norges Bank purchased a new position in shares of Viking Therapeutics in the 4th quarter worth about $51,464,000. Massachusetts Financial Services Co. MA increased its holdings in shares of Viking Therapeutics by 446.7% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,357,241 shares of the biotechnology company's stock worth $54,615,000 after buying an additional 1,108,972 shares during the period. Ameriprise Financial Inc. lifted its position in Viking Therapeutics by 228.5% in the fourth quarter. Ameriprise Financial Inc. now owns 1,479,596 shares of the biotechnology company's stock valued at $59,540,000 after purchasing an additional 1,029,125 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Viking Therapeutics during the 4th quarter valued at $24,888,000. Finally, Man Group plc grew its stake in shares of Viking Therapeutics by 3,373.4% in the fourth quarter. Man Group plc now owns 448,732 shares of the biotechnology company's stock worth $18,057,000 after purchasing an additional 435,813 shares during the last quarter. Hedge funds and other institutional investors own 76.03% of the company's stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.